Biomerica IncBMRA
Price$2.24

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $4.5M-16.2% YoYTTM through 28 Feb 2026
Net Income -$3.8MTTM through 28 Feb 2026
Free Cash Flow -$3.4MTTM through 31 May 2026

Margins

Current
Gross Margin-4.5%
EBITDA Margin-117.7%
Operating Margin-131.5%
Net Margin-84.8%

Returns

-106.6%ROE
-97.6%ROA

Balance Sheet Health

Debt / Equity0.06x
Current Ratio2.64x
Net Debt-$1.1Mnet cash position
Cash & Equivalents$1.3M

Quality Metrics

Altman Z-Score-11.61
Piotroski F-Score2 / 9
FCF Margin-76.8%

Multi-Year Trend

Revenue
'20'21'22'23'24'25'26
FY2026: $4.5M
Diluted EPS-$1.30TTM
'20'21'22'23'24'25'26
FY2026: $-1.30

Dividend

No dividend

Capital Allocation

R&D Spend$788K
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.